- Conditions
- Neoplasms
- Interventions
- Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- MOR00208 (formerly Xmab5574)
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Memphis, Tennessee • Houston, Texas
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Maplirpacept, Tafasitamab, Lenalidomide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Baton Rouge, Louisiana • Ann Arbor, Michigan • Providence, Rhode Island
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Tafasitamab, Idelalisib, Venetoclax
- Biological · Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab, Lenalidomide
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 10
- States / cities
- Bakersfield, California • Los Angeles, California • Redondo Beach, California + 7 more
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- MOR00208 (formerly Xmab 5574)
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 4
- States / cities
- Norwalk, Connecticut • Hackensack, New Jersey • Columbus, Ohio + 1 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab, Tafasitamab plus lenalidomide
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Anaheim, California • Duarte, California + 20 more
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Not listed
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Clovis, California • Los Angeles, California + 18 more
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Not listed
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Rochester, Minnesota • St Louis, Missouri • Manhasset, New York + 5 more
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
- Interventions
- MOR00208, lenalidomide, Correlative Studies
- Biological · Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio